📊 WVE Key Takeaways
Is Wave Life Sciences Ltd. (WVE) a Good Investment?
Wave Life Sciences faces severe operational deterioration with revenue collapsing 60.5% YoY and generating negative free cash flow of -$60M annually. While the balance sheet provides near-term runway through substantial cash reserves, the unprofitable operations, declining sales, and negative margins indicate fundamental business failure, suggesting the core pipeline or commercial strategy is failing.
Wave Life Sciences Ltd. Key Strengths (WVE)
- Strong cash position of $544.6M provides operational runway for approximately 9 years at current burn rate
- Zero debt burden with Debt/Equity ratio of 0.00x and low liabilities of $71.8M
- Excellent liquidity ratios (Current Ratio 11.26x) enabling continued funding without asset sales or distress financing
WVE Stock Risks: Wave Life Sciences Ltd. Investment Risks
- Revenue collapsed 60.5% year-over-year indicating severe commercial or clinical setbacks in core products
- Negative free cash flow of -$60.0M annually with FCF margin of -156.9% showing operations are cash destructive
- Deeply unprofitable with operating margin of -81.8% and net margin of -68.2%, generating $26.1M net losses
- Diluted EPS deteriorated 72.9% YoY to -$0.13, reflecting worsening per-share economics
- Cash burn will deplete reserves within 9 years even if stabilized at current levels without positive cash flow inflection
Key Metrics to Watch
- Quarterly revenue trend stabilization or further deterioration
- Operating cash flow path to positive; current -$59.6M burn is unsustainable long-term
- Clinical trial pipeline progress and regulatory approval timeline for next-stage products
- Cash runway duration and monthly cash burn rate acceleration/deceleration
- Gross margin recovery upon successful product commercialization to offset operating losses
Wave Life Sciences Ltd. (WVE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.26x current ratio provides a solid financial cushion.
WVE Profit Margin, ROE & Profitability Analysis
WVE vs Healthcare Sector: How Wave Life Sciences Ltd. Compares
How Wave Life Sciences Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Wave Life Sciences Ltd. Stock Overvalued? WVE Valuation Analysis 2026
Based on fundamental analysis, Wave Life Sciences Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Wave Life Sciences Ltd. Balance Sheet: WVE Debt, Cash & Liquidity
WVE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Wave Life Sciences Ltd.'s revenue has grown significantly by 177% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.54 indicates the company is currently unprofitable.
WVE Revenue Growth, EPS Growth & YoY Performance
WVE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $9.2M | -$26.1M | $-0.13 |
| Q2 2025 | $8.7M | -$31.6M | $-0.25 |
| Q1 2025 | $9.2M | -$31.6M | $-0.24 |
| Q2 2024 | $19.7M | -$21.1M | $-0.20 |
| Q1 2024 | $12.5M | -$27.4M | $-0.24 |
| Q3 2023 | $285.0K | $7.3M | $0.07 |
| Q2 2023 | $375.0K | -$21.1M | $-0.20 |
| Q1 2023 | $1.8M | -$27.4M | $-0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Wave Life Sciences Ltd. Dividends, Buybacks & Capital Allocation
WVE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Wave Life Sciences Ltd. (CIK: 0001631574)
📋 Recent SEC Filings
❓ Frequently Asked Questions about WVE
What is the AI rating for WVE?
Wave Life Sciences Ltd. (WVE) has an AI grade of D with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are WVE's key strengths?
Claude: Strong cash position of $544.6M provides operational runway for approximately 9 years at current burn rate. Zero debt burden with Debt/Equity ratio of 0.00x and low liabilities of $71.8M.
What are the risks of investing in WVE?
Claude: Revenue collapsed 60.5% year-over-year indicating severe commercial or clinical setbacks in core products. Negative free cash flow of -$60.0M annually with FCF margin of -156.9% showing operations are cash destructive.
What is WVE's revenue and growth?
Wave Life Sciences Ltd. reported revenue of $38.2M.
Does WVE pay dividends?
Wave Life Sciences Ltd. does not currently pay dividends.
Where can I find WVE SEC filings?
Official SEC filings for Wave Life Sciences Ltd. (CIK: 0001631574) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is WVE's EPS?
Wave Life Sciences Ltd. has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is WVE's fundamental grade?
Based on our AI fundamental analysis in June 2026, Wave Life Sciences Ltd. has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is WVE stock overvalued or undervalued?
Valuation metrics for WVE: ROE of -5.1% (sector avg: 15%), net margin of -68.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is WVE's AI grade for 2026?
Our dual AI analysis gives Wave Life Sciences Ltd. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is WVE's free cash flow?
Wave Life Sciences Ltd.'s operating cash flow is $-59.6M, with capital expenditures of $438.0K. FCF margin is -156.9%.
How does WVE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -68.2% (avg: 12%), ROE -5.1% (avg: 15%), current ratio 11.26 (avg: 2).